These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32476507)

  • 1. Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data.
    Megna M; Cinelli E; Camela E; Fabbrocini G
    Expert Rev Clin Immunol; 2020 Jun; 16(6):599-620. PubMed ID: 32476507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile.
    Paul C; Bang B; Lebwohl M
    Expert Opin Pharmacother; 2017 Jan; 18(1):115-121. PubMed ID: 27936972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
    Bewley AP; Shear NH; Calzavara-Pinton PG; Hansen JB; Nyeland ME; Signorovitch J
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1107-1115. PubMed ID: 30472749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis.
    Foley P; Garrett S; Ryttig L
    Curr Med Res Opin; 2018 Jul; 34(7):1277-1283. PubMed ID: 29336190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
    Koo J; Tyring S; Werschler WP; Bruce S; Olesen M; Villumsen J; Bagel J
    J Dermatolog Treat; 2016; 27(2):120-7. PubMed ID: 26444907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.
    Queille-Roussel C; Olesen M; Villumsen J; Lacour JP
    Clin Drug Investig; 2015 Apr; 35(4):239-45. PubMed ID: 25708531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp.
    Kragballe K; van de Kerkhof P
    J Eur Acad Dermatol Venereol; 2014 May; 28 Suppl 2():10-21. PubMed ID: 24684739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden.
    Duvetorp A; Levin LÅ; Engerstedt Mattsson E; Ryttig L
    Acta Derm Venereol; 2019 Apr; 99(4):393-399. PubMed ID: 30628631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp.
    McCormack PL
    Drugs; 2011 Apr; 71(6):709-30. PubMed ID: 21504248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
    Paul C; Leonardi C; Menter A; Reich K; Gold LS; Warren RB; Møller A; Lebwohl M
    Am J Clin Dermatol; 2017 Jun; 18(3):405-411. PubMed ID: 28236223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation.
    Gallo L; Megna M; Cirillo T; Caterino P; Lodi G; Mozzillo R; Dente V; Balato A
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1312-1315. PubMed ID: 30767288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience.
    Fabbrocini G; Dauden E; Jalili A; Bewley A
    G Ital Dermatol Venereol; 2020 Apr; 155(2):212-219. PubMed ID: 32394674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
    Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
    J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcipotriol and betamethasone dipropionate exhibit different immunomodulatory effects on imiquimod-induced murine psoriasiform dermatitis.
    Takeoka S; Shimizu T; Kamata M; Hau CS; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2020 Feb; 47(2):155-162. PubMed ID: 31762070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
    Pink AE; Jalili A; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D; Torpet M; Jensen KL; Segaert S
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1116-1123. PubMed ID: 30916417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study.
    Lambert J; Hol CW; Vink J
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2349-55. PubMed ID: 26337069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis.
    Amat-Samaranch V; Puig L
    Expert Opin Drug Saf; 2020 Apr; 19(4):423-432. PubMed ID: 32243212
    [No Abstract]   [Full Text] [Related]  

  • 18. Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation.
    Purvis CG; Balogh EA; Heron CE; Feldman SR
    Expert Opin Pharmacother; 2021 Jun; 22(9):1107-1118. PubMed ID: 33745399
    [No Abstract]   [Full Text] [Related]  

  • 19. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.
    Griffiths CE; Stein Gold L; Cambazard F; Kalb RE; Lowson D; Møller A; Paul C
    Eur J Dermatol; 2018 Jun; 28(3):356-363. PubMed ID: 29952297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris.
    Queille-Roussel C; Nielsen J; Lacour JP
    J Dermatolog Treat; 2019 Sep; 30(6):529-533. PubMed ID: 30582717
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.